PharmaPoint: Chronic Obstructive Pulmonary Disease Global Drug Forecast and Market Analysis to 2025 [Report Updated: 30052017] Prices from USD $10995

09:50 EDT 2 Aug 2017 | BioPortfolio Report Blog

PharmaPoint: Chronic Obstructive Pulmonary Disease Global Drug Forecast and Market Analysis to 2025


Chronic obstructive pulmonary disease COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Research suggests that the pathogenesis of COPD involves both genetic and environmental factors. The fourth leading cause of death in the world, COPD progresses slowly and symptoms, including shortness of breath, wheezing, chest tightness, cough, and increased mucous production, worsen over time. Although it is currently unknown if the damage to the airways and lungs can be reversed, treatments and lifestyle changes can help slow the progress of the disease.

GlobalData estimates the 2015 sales for the COPD market at approximately $9.9 billion across the 8MM, encompassing the US, the five major European Union countries 5EU: France, Germany, Italy, Spain, and UK, Japan, and Australia. Over the course of the 10year forecast period, the COPD market will grow at a Compound Annual Growth Rate CAGR of 3.7% across the 8MM. Each of the 8MM are anticipated to grow significantly, recording CAGRs of 3.7%, 5.2%, 4.3%, and 6.6% across the US, 5EU, Japan, and Australia, respectively. At the end of 2025, the US will account for 77.8% of sales across the 8MM, while the 5EU, Japan, and Australia will account for around 19.2%, 2.4%, and 0.7% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of COPD in the region, as well as the anticipated high annual cost of therapy ACOT of GSK's Nucala and AstraZeneca's benralizumab in the US market.

Key Questions Answered

How will the COPD market landscape in the 8MM US, France, Germany, Italy, Spain, UK , Japan, and Australia change from 20152025?
What are the most promising latestage pipeline drugs in COPD?
How do the clinical and commercial attributes of latestage pipeline therapies compare with one another, and against existing treatment options?
What are the greatest unmet needs in COPD? Will the pipeline drugs fulfil these needs of the market?
What are the largest opportunities in the COPD landscape?


Overview of COPD, including epidemiology mMRC and CAT patient population, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline COPD market revenue from 20152025. ACOT and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative earlystage projects, and detailed analysis of latestage pipeline products.
Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to
Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global COPD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Original Article: PharmaPoint: Chronic Obstructive Pulmonary Disease Global Drug Forecast and Market Analysis to 2025 [Report Updated: 30052017] Prices from USD $10995


More From BioPortfolio on "PharmaPoint: Chronic Obstructive Pulmonary Disease Global Drug Forecast and Market Analysis to 2025 [Report Updated: 30052017] Prices from USD $10995"

Quick Search

Relevant Topics

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...